According to the latest report by IMARC Group, titled “Migraine Drugs Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027″ The global migraine treatment market share reached US$ 3.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.57% during 2022-2027.

Migraine is a neurological condition that causes severe headache accompanied with various autonomic symptoms, such as nausea, vomiting, photophobia, and phonophobia. The diagnosis of this condition is determined based on patient clinical history, reported symptoms, magnetic resonance imaging, and computerized tomography scans. Currently, over-the-counter (OTC) medicines and prescribed injections are widely available to relieve the symptoms and reduce the frequency of migraine attacks. These medicines are either administered regularly or during attacks of chronic pain.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample

Global Migraine Drugs Market Trends:

The high prevalence of migraine based on the hectic consumer work schedules and sedentary lifestyles is augmenting the demand for migraine drugs. Moreover, several improvements in the reimbursement policies for migraine medications, along with the growing demand for precision drugs, are also augmenting the market growth. Furthermore, the increasing adoption of electrical nerve stimulating devices to treat migraine and faster drug approvals by several regulatory bodies are also propelling the global market. In addition to this, the introduction of calcitonin gene-related peptide (CGRP)-based therapies is expected to further drive the global market for migraine drugs.

Key Market Segmentation:

Our report has categorized the market based on region, treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

Abortive Treatment
Preventive Treatment

Breakup by Drug Type:

Triptans
Ergot Alkaloids
NSAIDs
Acetylcholine Inhibitors/ Neurotoxins
Ditans
CGRP mAbs
Others

Breakup by Route of Administration:

Oral
Injectable
Others

Breakup by Distribution Channel:

Hospital-Based Pharmacies
Retail Pharmacies
Others

Breakup by Region:

North America: (United States, Canada)
Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa

Competitive Landscape Key Player:

Abbott LaboratoriesAllergan Plc (Abbvie Inc.)Amgen Inc.AstraZeneca PlcBausch Health Companies Inc. (formerly Valeant Pharmaceuticals)Eisai Co. Ltd.Eli Lilly and CompanyEndo International PlcGlaxoSmithKline PlcJohnson & JohnsonMerck & Co.Novartis AGPfizer Inc.Sanofi SATeva Pharmaceutical Industries Limited

Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800